COST ANALYSIS OF CHEMOTHERAPY AND JUDGING THE QUALITY OF LIFE IN BREAST CANCER PATIENTS IN Hospital DR. Moewardi
ABSTRACT: Breast cancer is the most common type of cancer in women, other than cervical cancer. The main problem associated with the treatment of breast cancer is the cost of treatment and the decline of quality of life due to side effects of chemotherapy. This study was conducted to describe the characteristics of the patients, the amount of direct medical costs and the quality of life of breast cancer patients. This study was a cross-sectional observational study with a perspective of the hospital. Subjects were breast cancer outpatients who are undergoing chemotherapy in June-July 2013. Data collection was done in two ways, concurrent and retrospective. The quality of life of patients seen by using the EORTC QLQ-C30 instrument. One-way ANOVA test, Kruskal-Wallis and Mann-Whitney were used for the analysis. The results showed that the characteristics of patients mostly at the age 45-55 years, 20 (52.63%) with stage IIIB as the most stage, 14 (36.84%). Chemotherapy regimens most widely used is Cyclophosphamide, Adriamycin and 5-Florouracil (CAF), 20 (52.63%). The highest average total direct medical costs are Taxotere, Epirubicin and Cyclophosphamide (TEC) with an average of Rp 10,204,051 ± 1,505,697. Lowest medical costs in the AC regimen with an average of Rp 1,190,833 ± 497,790. Analysis of the relationship of patient characteristics with the EORTC QLQ-C30 scales showed significant differences between age and emotional functioning (p=0.019), sleep disturbance (p=0.013) and the financial impact (p=0.001). Stage of breast cancer and chemotherapy cycles did not have significant differences to the scale of the EORTC QLQ-C30 (p>0.05). There are significant differences between the regimens of chemotherapy with nausea and vomiting (p=0.044).
